Get the Stockscreener App
18.70
2.22%
-0.4301
Acadia Pharmaceuticals Inc stock is traded at $18.70, with a volume of 565.37K.
It is down -2.22% in the last 24 hours and up +7.56% over the past month.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$19.13
Open:
$19.06
24h Volume:
565.37K
Relative Volume:
0.25
Market Cap:
$3.18B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
103.89
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+0.24%
1M Performance:
+7.56%
6M Performance:
+23.30%
1Y Performance:
-25.80%
1-Day Range:
$18.58
$19.14
1-Week Range:
$18.04
$19.70
52-Week Range:
$14.15
$26.78
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
18.68 | 3.18B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.22 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.74 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
BlackRock, Inc. Increases Stake in ACADIA Pharmaceuticals Inc. - GuruFocus.com
High Growth Tech Stocks To Watch In February 2025 - Simply Wall St
Schizophrenia Market Expected to rise, 2034 | Boehringer - openPR
ACADIA Pharmaceuticals Trying To Close In On Key Technical Measure - Investor's Business Daily
Leerink Partnrs Brokers Increase Earnings Estimates for ACAD - MarketBeat
Leerink Partnrs Has Optimistic Outlook of ACAD Q4 Earnings - MarketBeat
DCGI nod to Bajaj Healthcare for manufacturing Parkinson's disease psychosis drug Pimavanserin in India - Medical Dialogues
ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid mixed product performance - MSN
3 Hidden Bargains in the Healthcare Sector - Inkl
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
Acadia’s New CEO Outlines Growth Strategy - News & Insights
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.25 - MarketBeat
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Up 6.4%Still a Buy? - MarketBeat
Research Analysts Offer Predictions for ACAD FY2025 Earnings - Defense World
Brokers Issue Forecasts for ACAD FY2025 Earnings - MarketBeat
SG Americas Securities LLC Increases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis - MarketBeat
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 6.9%Time to Sell? - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
JPM25: After taking the wheel at Acadia, CEO Catherine Owen Adams looks to steer firm toward $1B in sales - FiercePharma
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Up 14.5% in December - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - Defense World
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised) - MSN
Burney Co. Purchases New Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Neuren partner submits Rett drug for EU approval - NT News
Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expa - GuruFocus.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 6.9%Time to Sell? - MarketBeat
Acadia expects more than $1B in sales for 2025 - MSN
Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 - Yahoo Finance
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome - Agenzia ANSA
Acadia seeks EMA nod for first Rett syndrome therapy - Investing.com India
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
Acadia Pharma (ACAD) Submits Marketing Authorization Application to the EMA for Trofinetide for the Treatment of Rett Syndrome - StreetInsider.com
(ACAD) Proactive Strategies - Stock Traders Daily
Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61% - Yahoo Finance
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S - Simply Wall St
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acadia Pharmaceuticals Inc Stock (ACAD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Nov 19 '24 |
Sale |
16.81 |
4,073 |
68,467 |
19,863 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Nov 19 '24 |
Sale |
16.81 |
10,259 |
172,454 |
53,302 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 19 '24 |
Sale |
15.28 |
9,733 |
148,720 |
43,735 |
| Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL |
Aug 19 '24 |
Sale |
15.28 |
9,534 |
145,680 |
52,177 |
| DAVIS STEPHEN | CEO |
Aug 19 '24 |
Sale |
15.28 |
31,747 |
485,094 |
186,555 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Jun 10 '24 |
Sale |
14.79 |
975 |
14,420 |
34,564 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
May 02 '24 |
Sale |
16.94 |
3,503 |
59,341 |
32,053 |
| Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL |
May 02 '24 |
Sale |
16.94 |
3,477 |
58,900 |
42,133 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 02 '24 |
Sale |
16.94 |
1,326 |
22,462 |
14,370 |
| DAVIS STEPHEN | CEO |
May 02 '24 |
Sale |
16.94 |
11,427 |
193,573 |
155,231 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):